arrow
E

Edward V. Loftus

Mayo Clinic College of Medicine and Science
H指数:127
被引数:6.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression

溃疡性结肠炎患者术前接受高级疗法后术后并发症的对比风险:一项包含Meta回归的网络Meta分析

2026-08-080
PRE
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial

克罗恩病皮下注射英夫利昔单抗个性化治疗中的症状反应动力学:来自随机、安慰剂对照III期LIBERTY-CD试验的见解

2026-03-300
OAAI
Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease

乌帕替尼的获益-风险特征:中度至重度活动性溃疡性结肠炎或克罗恩病患者2b/3期研究的探索性事后分析

2026-01-011
PRE
Comparative efficacy of immunomodulators, biologics, and advanced therapies for steroid-refractory acute severe ulcerative colitis: A network meta-analysis and time-to-event analysis

免疫调节剂、生物制剂和先进疗法对糖皮质激素难治性急性重度溃疡性结肠炎的疗效比较:一项网络Meta分析和时间至事件分析

2025-11-030
PRE
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease

在基线使用皮质类固醇的中度至重度活动性克罗恩病患者中,乌帕替尼的疗效与安全性。

2025-11-011
OAAI
Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn’s disease: A prospective observational study

溃疡性结肠炎/克罗恩病患者中 vedolizumab 的长期安全性:一项前瞻性观察研究

2025-10-130
PRE
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial

在True North III期临床试验中,先前生物制剂暴露对Ozanimod疗效和安全性的影响

2025-10-012
PRE
Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, in Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-Ranging Trial

伊克罗金拉(Icotrokinra)在溃疡性结肠炎中的疗效与安全性:一项2b期剂量范围试验ANTHEM-UC第28周的结果,伊克罗金拉是一种靶向口服肽,可选择性地阻断IL-23受体激活。

2025-10-010
PRE
One Subcutaneous Injection of Mirikizumab Is Bioequivalent to 2 Subcutaneous Injections: Results From a Pharmacokinetic Comparability Study in Healthy Participants

单次皮下注射Mirikizumab与两次皮下注射生物等效:来自健康受试者药代动力学可比性研究的结果

2025-10-010
PRE
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials

国际共识:肠道超声在炎症性肠病试验中的应用

2025-09-011
PRE
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn’s Disease Trials and Clinical Practice

国际磁共振成像共识(用于管腔克罗恩病试验和临床实践)

2025-08-270
PRE
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program

评估年龄对溃疡性结肠炎患者中Etrasimod安全性和有效性的影响:ELEVATE UC临床项目数据的回顾性分析

2025-04-040
PRE